Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Breast Cancer Research and Treatment|February 15, 2011
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trialOleg Gluz, Peter Wild, Cornelia Liedtke, et al.
Breast Cancer Research : BCR|May 16, 2020
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trialCornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|January 12, 2025
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiativeLisa Hirschberg, Franziska Henze, Kerstin Paradies, et al.
Cancer Treatment Reviews|October 20, 2023
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapyNadia Harbeck, Ronald Kates, Timo Schinköthe, et al.
International Journal of Cancer|March 7, 2016
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trialPhilip C Schouten, Oleg Gluz, Nadia Harbeck, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 17, 2017
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2βMieke Raap, Malte Gronewold, Henriette Christgen, et al.
Breast (Edinburgh, Scotland)|February 6, 2021
Breast cancer surgery with augmented realityPedro F Gouveia, Joana Costa, Pedro Morgado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Pageof 5